Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

Figure 3

(a) Overall survival (OS) of patients with an interleukin-15 (IL-15) ≥ 76.5 pg/mL versus patients with an IL-15 < 76.5 pg/mL. The median OS was not reached in the group of patients with an IL-15 ≥ 76.5 pg/mL and 19.2 months with the group of patients with an IL-15, 76.5 pg/mL. The OS rates at 3 years were 79% and 47%, respectively (𝑃<.002). (b) Progression-free survival (PFS) of patients with an interleukin-15 (IL-15) ≥ 76.5 pg/mL versus patients with an IL-15 < 76.5 pg/mL. The median PFS was not reached in the group of patients with an IL-15 ≥ 76.5 pg/mL and 6.8 months with the group of patients with an IL-15, 76.5 pg/mL. The PFS rates at 3 years were 64% and 31%, respectively (𝑃<.002).

(a)

(b)